why is there a shortage of semaglutide An Ongoing Crisis: Raises Dual Concerns for Obesity and Diabetes Treatment Digital Health Law Firm |

A retrospective analysis shows a significant reduction in BMI with GLP-1s but no meaningful benefit in disability or disease progression in multiple sclerosis.

Read the article now!

A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial results reported at AAIC.

In 2026, fake products may visually resemble legitimate packaging almost perfectly

The company plans to start assessing the effects of semaglutide, the active ingredient in Ozempic, and other medicines on alcohol consumption this month in a newly announced clinical trial in alcohol-related liver disease although cutting drinking isnt the studys main goal.